---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-178978"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:36:40.763667+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# OnKure reports Q2 net loss $15.4M; OKI-219 trial data expected Q4 2025

## Summary
- Cash $83.4M as of June 30, 2025; runway expected into Q4 2026.
- Q2 net loss $15.4M ($1.14/sh) vs $14.1M ($44.82/sh) YoY; R&D spend rose to $12.6M.
- Completed enrollment in monotherapy and fulvestrant combo arms; data from both due Q4 2025.
- New triplet arm initiated: OKI-219 + fulvestrant + ribociclib in HR+ metastatic breast cancer.
- New triplet arm: OKI-219 + trastuzumab + tucatinib in HER2+ breast cancer; pan-mutant candidate nomination by year-end.

## SEC filing metadata
- accession: 0001193125-25-178978
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000119312525178978/0001193125-25-178978-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000119312525178978/okur-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-178978
- JSON: https://secwatch.observer/filing/0001193125-25-178978.json
- Plain text: https://secwatch.observer/filing/0001193125-25-178978.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.